Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...